Gennex Laboratories Reports Mixed Financial Results Amid Rising Sales in March 2025

Gennex Laboratories, a microcap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending March 2025. The results indicate a notable shift in the company's evaluation, with a revision in its score reflecting the current financial landscape. On a positive note, Gennex Laboratories achieved its highest quarterly net sales in the last five quarters, reaching Rs 44.16 crore, which represents a year-on-year growth of 24.32%. This upward trend in sales suggests a favorable near-term outlook for revenue generation. Conversely, several key financial metrics indicate challenges for the company. Profit Before Tax less Other Income (PBT) has shown a decline, landing at Rs 4.10 crore, marking a significant year-on-year decrease of 22.64%. Additionally, Profit After Tax (PAT) has also fallen sharply to Rs 2.32 crore, reflecting a year-on-year drop of 48.4%. Operating Profit and Operating Profit Margin have reached their lowest points in the last five quarters, indicating a decline in operational efficiency. Furthermore, Earnings per Share (EPS) has decreased to Rs 0.10, highlighting a reduction in profitability for shareholders. Overall, Gennex Laboratories' recent financial results reveal a complex picture, with both positive sales growth and significant challenges in profitability and operational performance. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.